跳至主要内容
临床试验/NCT06537466
NCT06537466尚未招募不适用

A Randomised Controlled Tria of Low-calorie Ketogenic Diet Versus Mediterranean Diet in Patients With Compensated Advanced Chronic Liver Disease (cACLD) Secondary to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

University of Palermo1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2024年11月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
50
试验地点
1
主要终点
weight loss≥10% compared to the initial weight in individuals with cACLD secondary to MASLD

研究概览

简要总结

The investigators hypothesize that very low ketogenic diet could represent a new therapeutic option in the management of patients with MASLD and cACLD. Therefore, the investigator propose a randomized controlled study that evaluates the impact of two dietary protocols -Mediterranean diet, and very low ketogenic diet- the MD and the VLCKD, in individuals with cACLD secondary to MASLD.

详细描述

The rationale of the study stems from evidence that patients with "compensated advanced chronic liver disease" (cACLD) secondary to MASLD have higher risk of liver-related morbidity (liver decompensation, hepatocellular carcinoma) and mortality. However, todate the only approved drug by FDA in patients with MASH and F2-F3 fibrosis is Resmetirom, but it is still not available in clinical practice outside US. As a consequence, currently and in the future the first-line treatment of MASLD involved weight loss and lifestyle modification, such as physical exercise and dietary regimens based on calorie restriction. In this context the Mediterranean diet is considered the standard, but over the last decade, the Very low-carbohydrate ketogenic diets (VLCKD) has gained immense popularity for its short-term positive effects on weight loss, even if data on MASLD cACLD are lacking.

Therefore, considering recent evidence, the investigator hypothesize that VLCKD could represent a new therapeutic option in the management of patients with MASLD and cACLD. Specifically, the investigator propose a randomized controlled study that evaluates the 48 week impact of two dietary protocols, the MD and the VLCKD, in individuals with cACLD secondary to MASLD, with specific focus on weight loss >=10% and on liver-related (changes in liver stiffness by TE, MRE and MRI-PDFF, AST, ALT) and metabolic parameters (see section on outcomes) Here the investigators report the detailed proposed nutritional protocols

  • MEDITERRANEAN DIET This equilibrated diet has a caloric value 10% below the total metabolic expenditure of each individual. The total metabolic expenditure is calculated from the basal metabolic expenditure (based on the formula FAO/WHO/UN) multiplied by the coefficient of activity, which is calculated according to the physical activity of each participant. The calories provide to this group range between 1,400 and 1,800 kcal/day. The ration of macronutrients provided is 45-55 % arbohydrates,15-25 % proteins, and 25-35 % fat, in addition to a recommended intake of 20-40 g/day of fiber in the form of vegetables and fruits.
  • VERY LOW-CARBOHYDRATE KETOGENIC DIETS The VLCKD ketogenic protocol entails: a caloric intake < 800 calories, a protein intake calculated based on individual needs: 1.2 + 0.2 g/kg/ideal body weight, low carbohydrate content (approximately 45-55 g of carbohydrates per day), and low lipids (10-15g/day). Vitamins and minerals, Unlimited vegetables.

The Kalibra protocol consists of 3 stages:

WEIGHT LOSS: Ketogenic metabolism is activated by reduced carbohydrate intake. As an accessory phenomenon to lipolysis and the catabolism of fat reserves in adipose tissue, there is a physiological production of ketone bodies (acetoacetate, beta-hydroxybutyrate, acetone), which represent a water-soluble and readily available energy source for many tissues in the body (brain, heart, and muscles). Continuous ketogenesis, in addition to providing adequate energy intake, is important to ensure the absence of hunger and a feeling of overall well-being throughout the weight loss period.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients older than 18 years
  • Pattients with cACLD secondary MASLD. Specifically cACLD is defined as liver stiffness ≥10 KPa by Transient Elastography and/or fibrosis F3 or F4 at liver biopsy by Kleiner scoring system; MASLD is defined by the presence of steatosis and at least one of five cardiometabolic risk factor.
  • Informed consent form obtained before any trial-related ac.vity.

排除标准

  • Concomitance of any other chronic liver disease: Wilson's disease (normal serum ceruloplasmin); alpha-1-an.trypsin deficiency (normal serum alpha-1-an.trypsin); viral hepatitis (anti-HCV and HBsAg negativity); primary biliary cirrhosis (ANA&lt;1:160 and AMA negativity); autoimmune hepatitis (ANA, SMA and LKM &lt;1:160), . .
  • MetALD: patients with metabolic dysfunc.on-associated steato.c liver disease, who consume amounts of alcohol per week (140-350 g/wk and 210-420 g/wk for females and males, respectively.
  • History of or planned gastrointestinal bypass or any additional bariatric surgery/intervention.
  • Recent significant weight loss ( &gt; 5 % within previous 6 months)
  • Presence of large esophageal varices (F2 or F3)
  • Decompensated liver cirrhosis and/or presence of hepatocarcinoma and/or portal thrombosis.
  • Be pregnant or breasxeeding.
  • Type 1 diabetes, cardiac arrhythmias, recent stroke or myocardial infarction, heart failure, elective surgery or invasive procedures, chronic kidney disease (eGFR&lt;30 ml/min).
  • Therapy with SGLT-2 inhibitors and/or GLP-1 agonist started within 6 months of screening visit.
  • Recent (within 6 months of screening visit) or concomitant use of agents known to cause hepatic steatosis (corticosteroids, amiodarone, methotrexate, tamoxifen, tetracycline, high dose estrogens, valproic acid)
  • Any additional condition that might interfere with optimal participation in the study, according to investigators opinion

结局指标

主要结局

weight loss≥10% compared to the initial weight in individuals with cACLD secondary to MASLD

时间窗: 48 weeks

Weight in Kg

次要结局

  • ▪ changes in albumin serum levels(48 weeks)
  • ▪ changes in liver fat by Magnetic Resonance Imaging-proton density fat fraction (MRI-PDFF)(48 weeks)
  • ▪ changes in liver stiffness by Magnetic Resonance Elastography (MRE)(48 weeks)
  • ▪ changes in liver stiffness by transient elastography(48 weeks)
  • ▪ changes in liver fat by controlled attenuation parameter (CAP)(48 weeks)
  • ▪ changes in Spleen stiffness by Magnetic Resonance Elastography (MRE)(48 weeks)
  • ▪ changes in ALT serum levels(48 weeks)
  • ▪ changes in GGT serum levels(48 weeks)
  • ▪ changes in INR serum levels(48 weeks)
  • ▪ changes in Spleen stiffness by Transient Elastography(48 weeks)
  • ▪ changes in AST serum levels(48 weeks)
  • ▪ changes in alcaline phosphatase serum levels(48 weeks)
  • ▪ changes in bilirubin serum levels(48 weeks)
  • ▪ changes in total, HDL and LDL cholesterol serum levels(48 weeks)
  • ▪ changes in glucose serum levels(48 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Salvatore Petta

Associate Professor of Gastroenterology, MD, PhD

University of Palermo

研究点 (1)

Loading locations...

相似试验

Ketogenic Diet in MASLD-related cACLD | 临床试验